The 36-month beta value for VKTX is at 1.00. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VKTX is 103.61M, and currently, shorts hold a 17.08% of that float. The average trading volume for VKTX on September 04, 2024 was 3.96M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VKTX) stock’s latest price update
Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has dropped by -8.94 in relation to previous closing price of 64.12. Nevertheless, the company has seen a loss of -10.88% in its stock price over the last five trading days. zacks.com reported 2024-09-03 that VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
VKTX’s Market Performance
Viking Therapeutics Inc (VKTX) has seen a -10.88% fall in stock performance for the week, with a 10.07% gain in the past month and a -6.23% plunge in the past quarter. The volatility ratio for the week is 7.57%, and the volatility levels for the past 30 days are at 7.73% for VKTX. The simple moving average for the past 20 days is -2.44% for VKTX’s stock, with a 18.40% simple moving average for the past 200 days.
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with Morgan Stanley repeating the rating for VKTX by listing it as a “Overweight.” The predicted price for VKTX in the upcoming period, according to Morgan Stanley is $105 based on the research report published on June 27, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $116, previously predicting the price at $115. The rating they have provided for VKTX stocks is “Strong Buy” according to the report published on May 16th, 2024.
Oppenheimer gave a rating of “Outperform” to VKTX, setting the target price at $138 in the report published on March 26th of the current year.
VKTX Trading at 3.44% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.26% of loss for the given period.
Volatility was left at 7.73%, however, over the last 30 days, the volatility rate increased by 7.57%, as shares surge +12.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.71% upper at present.
During the last 5 trading sessions, VKTX fell by -10.88%, which changed the moving average for the period of 200-days by +422.74% in comparison to the 20-day moving average, which settled at $60.17. In addition, Viking Therapeutics Inc saw 213.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from Lian Brian, who sale 1,000 shares at the price of $69.90 back on Aug 21 ’24. After this action, Lian Brian now owns 2,354,927 shares of Viking Therapeutics Inc, valued at $69,900 using the latest closing price.
SINGLETON J MATTHEW, the Director of Viking Therapeutics Inc, sale 5,700 shares at $69.72 during a trade that took place back on Aug 21 ’24, which means that SINGLETON J MATTHEW is holding 9,500 shares at $397,430 based on the most recent closing price.
Stock Fundamentals for VKTX
Current profitability levels for the company are sitting at:
- -285.96 for the present operating margin
- 0.32 for the gross margin
The net margin for Viking Therapeutics Inc stands at -221.89. The total capital return value is set at -0.14. Equity return is now at value -14.80, with -14.36 for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -65.4. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -4452.75.
Currently, EBITDA for the company is -100.53 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 14739.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 37.69.
Conclusion
In conclusion, Viking Therapeutics Inc (VKTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
